Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy
JCO Oncology Practice · 2026
DOI: 10.1200/op-25-00543 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Sydney E Schultz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Hypercalcemia, Diphosphonates, Zoledronic Acid, Pamidronate. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The difference in time to serum calcium normalization and rates of subsequent refractory hypocalcemia between bisphosphonates requires further investigation. Our primary objective was to assess the difference in normalization of serum calcium between pamidronate and zoledronic acid during treatment of hypercalcemia of malignancy (HCM) and rates of subsequent, refractory hypocalcemia following therapy. METHODS A retrospective review of patients with cancer who received pamidronate or zoledronic acid inpatient at Mayo Clinic for treatment of HCM between January 2018 and January 2024 was conducted. Logistic regression evaluated the association between treatment groups and outcomes. Multivariable modeling was adjusted for baseline differences, including severity of hypercalcemia. RESULTS We evaluated 856 patients. The median age was 68 (IQR, 59-75) years, and 476 (55.6%) were male. The most common cancer diagnoses were lymphoma (n = 158, 18.5%), followed by multiple myeloma (n = 145, 16.9%) and lung cancer (n = 111, 13%). Overall, 292 (46.8%) patients and 154 (32.8%) patients achieved serum calcium normalization by hospital day 4 and day 7, respectively. The rate of normalization was similar between all bisphosphonates, regardless of pamidronate dose. Significantly higher rates of hypocalcemia were observed on day 4 for patients who received zoledronic acid 4 mg once compared with either dose (60 mg once and 90 mg once) of pamidronate (40.7% v 27.6% v 26.8%, P = .049, respectively). No significant difference in rates of hypocalcemia were observed on day 7 (56.8% v 50% v 42.9%, P = .26, respectively) and day 30 (39.1% v 39.0% v 37.5%, P = .50, respectively). CONCLUSION Bisphosphonates were equally efficacious in normalizing serum calcium in patients with HCM. Pamidronate 90 mg was not more efficacious than 60 mg. Rates of refractory hypocalcemia were similar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
- Department of Medical Oncology, Mayo Clinic, Rochester, MN.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
ORCID-Profile: Sydney E Schultz, Jason N Barreto, Yucai Wang, Grace M Choong, Nelson Leung
Zitieren
APA
Schultz, S. E., Barreto, J. N., Cole, K. C., Wang, Y., Choong, G. M., & Leung, N. (2026). Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy. JCO Oncology Practice. https://doi.org/10.1200/op-25-00543
Vancouver
Schultz SE, Barreto JN, Cole KC, Wang Y, Choong GM, Leung N. Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy. JCO Oncology Practice. 2026. doi:10.1200/op-25-00543
BibTeX
@article{Schultz2026,
author = {Schultz, Sydney E and Barreto, Jason N and Cole, Kristin C and Wang, Yucai and Choong, Grace M and Leung, Nelson},
title = {Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-25-00543}
}
EUVIMED